MediaAlpha: Okami Medical Gains FDA Clearance for SENDERO MAX Catheter in Embolization Portfolio

Okami Medical Expands Embolization Portfolio with FDA Clearance for SENDERO MAX Catheter

Okami Medical, a company based in Aliso Viejo, California, takes a significant step forward in its embolization product line with the recent FDA clearance for its SENDERO MAX Delivery Catheter. This device is designed to obstruct blood flow in peripheral arterial vessels ranging from 1.5mm to 9.0mm, further complementing Okami’s existing offerings, which include the SENDERO Microcatheter and LOBO® occluders. The SENDERO MAX is engineered for enhanced performance, featuring a hydrophilic coating and a stainless steel braid that improves trackability and precise placement of interventional devices. This advancement signifies a commitment to providing healthcare professionals with cutting-edge tools for vascular interventions.

The innovative design of the SENDERO MAX is aligned with the proprietary HDBRAID® technology utilized in LOBO occluders, which aims to reduce blood flow and expedite vessel closure. The catheter's lubricious PTFE inner liner ensures a low-friction delivery, which is critical for effective and efficient medical procedures. Rhonda Robb, President and CEO of Okami Medical, expresses enthusiasm about the new addition to their catheter portfolio, emphasizing that it allows physicians to treat patients more effectively. The SENDERO MAX is poised to enhance interventional radiology practices, providing a comprehensive solution that addresses the needs of both patients and healthcare providers.

Dr. Nima Kokabi, an Interventional Radiologist, highlights the advantages of the SENDERO and LOBO combination, stating that it offers improved treatment options that surpass traditional methods. This collaboration aims to elevate the standards of care in peripheral vessel occlusion, where precision and efficacy are paramount. Established in 2017 by Inceptus Medical, Okami Medical is dedicated to developing innovative devices that respond to the evolving demands of the healthcare landscape, supported by notable venture capital firms including Vensana Capital and U.S. Venture Partners (USVP).

In addition to its technological advancements, Okami Medical’s strategic partnerships and experienced leadership play a vital role in driving its growth in the medical device sector. The company’s focus on creating specialized tools for vascular interventions reflects a broader trend within the industry, where innovation is key to improving patient outcomes. As the healthcare field continues to evolve, Okami Medical is well-positioned to contribute to advancements in embolization techniques and improve overall patient care. For more information about Okami Medical and its products, visit their website at www.okamimedical.com.